Centene Corp vs Lam Research Corporation — how do they compare? Centene Corp trades at $66.75 (market cap $32.05B), while Lam Research Corporation trades at $328.34 (market cap $389.67B). The key difference: Lam Research Corporation is far larger — about 12.2× Centene Corp's market cap, and Lam Research Corporation pays a 0.33% dividend while Centene Corp pays none. Which is the better fit depends on your goals.
| CNC | LRCX | |
|---|---|---|
Market Cap | $32.05B | $389.67B |
Sector | Health | Technology |
52-Week High | $68.72 | $433.33 |
52-Week Low | $26.17 | $97.03 |
Enterprise Value | $21.10B | $387.83B |
Dividend Yield | — | 0.33% |
Signals from Pluang's Aura AI — not financial advice
Centene (CNC) trades at $66.94, up 0.57% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings beat estimates with EPS of $2.51 versus $1.09 expected, driven by margin recovery and cost control. The stock shows attractive valuation metrics, including a P/E of 8.06 and P/S of 0.16, while revenue growth remains robust at $194.78B in 2025.
Outlook is positive with a consensus price target of $71.00, though risks include Medicaid membership volatility and net income margin pressure. The company's raised 2026 EPS guidance and operational cash flow strength support upside potential, but investors should weigh competitive and regulatory challenges in the managed care sector.
Lam Research (LRCX) trades at $328.93, up 7.35% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 2025 revenue of $18.44B, net income of $5.36B (31.27% margin), and consistent earnings beats. Recent expansion into panel-level packaging and semiconductor workforce development initiatives position LRCX for continued AI-driven growth.
Outlook remains positive with 78% analyst buy ratings and $397.18 consensus price target, though elevated valuation ratios (P/E 54.06) and potential semiconductor cycle volatility present risks. The stock offers exposure to AI infrastructure growth but requires monitoring of competitive threats and capital expenditure trends.
Trailing returns across standard periods
Latest headlines on both assets
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.
Read more on CNC →Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →